scholarly journals Senior Adult Oncology Clinical Practice Guidelines in Oncology

2005 ◽  
Vol 3 (4) ◽  
pp. 572 ◽  
Keyword(s):  
Older Patients ◽  
Standard Treatment ◽  
The United States ◽  
Older Individuals ◽  
Patients With Cancer ◽  
Risks And Benefits ◽  
Geriatric Screening ◽  
Senior Adult ◽  
Recent Version ◽  
Prevalence Of Cancer

By 2030, researchers estimate that 20% of the U.S. population will be 65 years or older. More than 50% of all new cancers in the United States occur in this patient population. In addition, the increased incidence and prevalence of cancer in older patients and the increased lifespan of older adults mean that cancer in older individuals is becoming an increasingly common problem. Specific issues include geriatric screening and assessment, preventing or decreasing complications from therapy, accounting for disease-specific issues, and managing patients who cannot tolerate standard treatment. The NCCN Senior Adult Oncology Panel has developed guidelines for addressing these issues and for assessing the risks and benefits of treatment in older patients with cancer. For the most recent version of the guidelines, please visit NCCN.org

scholarly journals Relevance of a systematic geriatric screening and assessment in older patients with cancer: results of a prospective multicentric study

2013 ◽  
Vol 24 (5) ◽  
pp. 1306-1312 ◽  
Author(s):  
C. Kenis ◽  
D. Bron ◽  
Y. Libert ◽  
L. Decoster ◽  
K. Van Puyvelde ◽  
...  
Keyword(s):  
Older Patients ◽  
Multicentric Study ◽  
Patients With Cancer ◽  
Geriatric Screening

Cancer-Related Fatigue

2007 ◽  
Vol 5 (10) ◽  
pp. 1054 ◽  
Author(s):  
_ _
Keyword(s):  
Bone Marrow ◽  
Radiation Therapy ◽  
Cytotoxic Chemotherapy ◽  
Common Symptom ◽  
Patients With Cancer ◽  
Cancer Related Fatigue ◽  
Biologic Response ◽  
Dose Dense ◽  
Recent Version ◽  
Prevalence Of Cancer

Fatigue is a common symptom in patients with cancer and is nearly universal in those undergoing cytotoxic chemotherapy, radiation therapy, bone marrow transplantation, or treatment with biologic response modifiers. The problem, which affects 70% to 100% of cancer patients, has been exacerbated by the increased use of fatigue-inducing multimodal treatments and dose-dense, dose-intense protocols. In patients with metastatic disease, the prevalence of cancer-related fatigue exceeds 75%, and cancer survivors report that fatigue is a disruptive symptom months or even years after treatment ends. Patients perceive fatigue to be the most distressing symptom associated with cancer and its treatment, more distressing even than pain or nausea and vomiting, which, for most patients, can generally be managed with medications. For the most recent version of the guidelines, please visit NCCN.org

Cancer- and Chemotherapy-Induced Anemia

2008 ◽  
Vol 6 (6) ◽  
pp. 536 ◽  
Author(s):  
_ _
Keyword(s):  
Cancer Patients ◽  
Treatment Options ◽  
Red Blood Cell Transfusion ◽  
Common Condition ◽  
Packed Red Blood Cells ◽  
Patients With Cancer ◽  
Risks And Benefits ◽  
Parenteral Iron ◽  
Recent Version ◽  
Care Measure

Anemia is a common condition in patients with cancer, and its correction through either transfusion with packed red blood cells or the administration of erythropoiesis-stimulating agents (ESAs) is a supportive care measure. The purpose of the guidelines is to operationalize the evaluation and treatment of anemia in cancer patients and to enable patients and clinicians to evaluate treatment options in the context of risks and benefits. The updated guidelines include a number of important changes that respond to new FDA recommendations limiting the use of ESAs in cancer patients. Updates also include new tables on the risks and benefits of ESAs versus red blood cell transfusion and recommendations for administering parenteral iron products. For the most recent version of the guidelines, please visit NCCN.org

The novel geriatric screening tool and retrospective validation in older patients with cancer

2014 ◽  
Vol 5 ◽  
pp. S16-S17
Author(s):  
J.W. Kim ◽  
S.-H. Kim ◽  
Y.J. Kim ◽  
K.-W. Lee ◽  
J.-O. Lee ◽  
...  
Keyword(s):  
Older Patients ◽  
Screening Tool ◽  
The Novel ◽  
Patients With Cancer ◽  
Geriatric Screening

Geriatric screening and assessment among older patients with cancer: evaluation of long-term outcomes in a multicentric cohort of > 7, 000 patients

2021 ◽  
Vol 12 (8) ◽  
pp. S63-S64
Author(s):  
V. Depoorter ◽  
K. Vanschoenbeek ◽  
L. Decoster ◽  
H. De Schutter ◽  
P.R. Debruyne ◽  
...  
Keyword(s):  
Older Patients ◽  
Long Term Outcomes ◽  
Patients With Cancer ◽  
Geriatric Screening

scholarly journals A Novel Geriatric Screening Tool in Older Patients with Cancer: The Korean Cancer Study Group Geriatric Score (KG)-7

PLoS ONE ◽  
2015 ◽  
Vol 10 (9) ◽  
pp. e0138304 ◽  
Author(s):  
Jin Won Kim ◽  
Se-Hyun Kim ◽  
Yu Jung Kim ◽  
Keun-Wook Lee ◽  
Kwang-Il Kim ◽  
...  
Keyword(s):  
Older Patients ◽  
Screening Tool ◽  
Study Group ◽  
Cancer Study ◽  
Patients With Cancer ◽  
Cancer Study Group ◽  
Geriatric Screening

Performance of Two Geriatric Screening Tools in Older Patients With Cancer

2014 ◽  
Vol 32 (1) ◽  
pp. 19-26 ◽  
Author(s):  
Cindy Kenis ◽  
Lore Decoster ◽  
Katrien Van Puyvelde ◽  
Jacques De Grève ◽  
Godelieve Conings ◽  
...  
Keyword(s):  
Activities Of Daily Living ◽  
Daily Living ◽  
Older Patients ◽  
Prognostic Value ◽  
Functional Decline ◽  
Treatment Decision ◽  
Risk Profile ◽  
Screening Tools ◽  
Patients With Cancer ◽  
Geriatric Screening

Purpose To compare the diagnostic characteristics of two geriatric screening tools (G8 and Flemish version of the Triage Risk Screening Tool [fTRST]) to identify patients with a geriatric risk profile and to evaluate their prognostic value for functional decline and overall survival (OS). Patients and Methods Patients ≥ 70 years old with a malignant tumor were included if a new cancer event occurred requiring treatment decision. Geriatric screening with G8 and fTRST (cutoff ≥ 1 [fTRST (1)] and ≥ 2 [fTRST (2)] evaluated) was performed in all patients, as well as a geriatric assessment (GA) evaluating social situation, functionality (activities of daily living [ADL] + instrumental activities of daily living [IADL]), cognition, depression, and nutrition. Functionality was re-evaluated 2 to 3 months after cancer treatment decision, and death rate was followed. Functional decline and OS were evaluated in relation to normal versus abnormal score on both screening tools. Results Nine hundred thirty-seven patients were included (October 2009 to July 2011). G8 and fTRST (1) showed high sensitivity (86.5% to 91.3%) and moderate negative predictive value (61.3% to 63.4%) to detect patients with a geriatric risk profile. G8 and fTRST (1) were strongly prognostic for functional decline on ADL and IADL, and G8, fTRST (1), and fTRST (2) were prognostic for OS (all P < .001). G8 had the strongest prognostic value for OS (hazard ratio for G8 normal v abnormal, 0.38; 95% CI, 0.27 to 0.52). Conclusion Both geriatric screening tools, G8 and fTRST, are simple and useful instruments in older patients with cancer for identifying patients with a geriatric risk profile and have a strong prognostic value for functional decline and OS.

Balancing the risks and benefits of antipsychotic medications for symptom management in older patients with cancer

2018 ◽  
Vol 9 (6) ◽  
pp. 693-695
Author(s):  
Rosa Liperoti ◽  
Domenico Fusco ◽  
Maria C. Cipriani ◽  
Maria R. Lo Monaco ◽  
Graziano Onder
Keyword(s):  
Symptom Management ◽  
Older Patients ◽  
Antipsychotic Medications ◽  
Patients With Cancer ◽  
Risks And Benefits
Sign in / Sign up

Export Citation Format

Share Document